表紙
市場調查報告書

焦點市場分析:基底細胞癌

Market Spotlight: Basal Cell Carcinoma

出版商 Datamonitor Healthcare 商品編碼 633154
出版日期 內容資訊 英文 32 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:基底細胞癌 Market Spotlight: Basal Cell Carcinoma
出版日期: 2019年11月27日內容資訊: 英文 32 Pages
簡介

本報告提供全球基底細胞癌市場相關調查,彙整基底細胞癌概要和治療,已上市及近幾年的開發平台藥物,收益的機會,臨床實驗趨勢等相關資訊。

概要

疾病概要

  • 基底細胞癌的亞型

治療

  • 電極清宮術(ED&C)
  • 莫爾斯顯微鏡手術
  • 放射治療
  • 冷凍治療
  • 光動力療法(PDT)
  • 雷射手術
  • 醫療行為

流行病學

  • 近幾年的發病趨勢調查

已上市藥物

  • 該國認證
  • 美國的開發平台藥物

主要的法律規章活動

授權與資產收購契約

  • Sun收購Novartis Cancer Drug

專利

商機

臨床實驗趨勢

參考文獻

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0189916

This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, reactive oxygen species/free radicals, and Hedgehog signaling pathway. The majority of these therapies are administered via the topical route, with the remainder being oral formulations.

The greatest proportion of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II, with two drugs in Phase III.

Therapies in the pipeline for basal cell carcinoma focus on a wide variety of targets. These drugs are administered via the topical, oral, intravenous, and intratumoral routes.

High-impact upcoming events for drugs in the basal cell carcinoma space comprise topline Phase II trial results for Libtayo and topline Phase III trial results for Ameluz.

The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 41%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been five licensing and asset acquisition deals involving basal cell carcinoma drugs during 2014-19. The $175m agreement between Sun Pharmaceutical and Novartis made in December 2016 for the acquisition of Novartis's branded oncology product Odomzo by Sun Pharmaceutical was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for basal cell carcinoma have been in the early and mid-phases of development, with 80% of trials in Phase I-II, and only 20% in Phase III-IV.

The US has a substantial lead in the number of basal cell carcinoma clinical trials globally, while the UK leads the major EU markets.

Clinical trial activity in the basal cell carcinoma space is dominated by completed trials. Roche has the highest number of completed clinical trials for basal cell carcinoma, with 17 trials.

Roche leads industry sponsors with the highest overall number of clinical trials for basal cell carcinoma, followed by Novartis.

TABLE OF CONTENTS

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

7 Subtypes

8 TREATMENT

8 Electrodesiccation and curettage (ED&C)

8 Mohs micrographic surgery

8 Excisional surgery

8 Radiation therapy

9 Cryosurgery

9 Photodynamic therapy (PDT)

9 Laser surgery

9 Pharmacological therapies

11 EPIDEMIOLOGY

11 Recent incidence studies

12 MARKETED DRUGS

14 PIPELINE DRUGS

19 RECENT EVENTS AND ANALYST OPINION

19 SRT-100 for Basal Cell Carcinoma (April 23, 2019)

20 Erivedge for Basal Cell Carcinoma (March 25, 2019)

22 KEY UPCOMING EVENTS

23 PROBABILITY OF SUCCESS

24 LICENSING AND ASSET ACQUISITION DEALS

25 PARENT PATENTS

26 CLINICAL TRIAL LANDSCAPE

27 Sponsors by status

28 Sponsors by phase

29 Recent events

30 BIBLIOGRAPHY

30 Prescription information

31 APPENDIX

LIST OF FIGURES

  • 14 Figure 1: Overview of pipeline drugs for basal cell carcinoma in the US
  • 14 Figure 2: Pipeline drugs for basal cell carcinoma, by company
  • 15 Figure 3: Pipeline drugs for basal cell carcinoma, by drug type
  • 15 Figure 4: Pipeline drugs for basal cell carcinoma, by classification
  • 22 Figure 5: Key upcoming events in basal cell carcinoma
  • 23 Figure 6: Probability of success in the basal cell carcinoma pipeline
  • 24 Figure 7: Licensing and asset acquisition deals in basal cell carcinoma, 2014-19
  • 25 Figure 8: Parent patents in basal cell carcinoma
  • 26 Figure 9: Clinical trials in basal cell carcinoma
  • 26 Figure 10: Top 10 drugs for clinical trials in basal cell carcinoma
  • 27 Figure 11: Top 10 companies for clinical trials in basal cell carcinoma
  • 27 Figure 12: Trial locations in basal cell carcinoma
  • 28 Figure 13: Basal cell carcinoma trials status
  • 29 Figure 14: Basal cell carcinoma trials sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Marketed drugs for basal cell carcinoma
  • 16 Table 2: Pipeline drugs for basal cell carcinoma in the US
  • 19 Table 3: SRT-100 for Basal Cell Carcinoma (April 23, 2019)
  • 20 Table 4: Erivedge for Basal Cell Carcinoma (March 25, 2019)